Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00244764 · ClinicalTrials.gov registry record · Phase 2

GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma

A Phase 2 study of Carcinoma, Renal Cell, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 2
Development phase
225
Enrollment target
20
Study locations

NCT00244764 is a Phase 2 study of Carcinoma, Renal Cell that has completed, run by GlaxoSmithKline. The registered enrollment target is 225 participants, below the 277-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (19% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00244764, a Phase 2 study of Carcinoma, Renal Cell, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 2
Development phase
225 participants
Enrollment target
20
Study locations

Study Summary

Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.

Conditions Studied

Carcinoma, Renal Cell

Interventions

  • DRUG Placebo
  • DRUG GW786034

Study Locations (20)

California

  • GSK Investigational Site - Duarte
  • GSK Investigational Site - Los Angeles
  • GSK Investigational Site - Orange
  • GSK Investigational Site - San Francisco

Victoria

  • GSK Investigational Site - East Melbourne
  • GSK Investigational Site - Footscay
  • GSK Investigational Site - Heidelberg
  • GSK Investigational Site - Parkville

New South Wales

  • GSK Investigational Site - Camperdown
  • GSK Investigational Site - Kogarah
  • GSK Investigational Site - Randwick

Ohio

  • GSK Investigational Site - Cleveland
  • GSK Investigational Site - Cleveland

Colorado

  • GSK Investigational Site - Aurora

Georgia

  • GSK Investigational Site - Tucker

Indiana

  • GSK Investigational Site - Indianapolis

New York

  • GSK Investigational Site - New York

Trial Details

FieldValue
Enrollment Target 225 participants
Start Date 2005-10
Est. Completion 2013-09
Phase Phase 2

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00244764

The ClinicalTrials.gov registry entry for NCT00244764 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 277-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (19% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00244764 reports 20 study locations spanning 11 distinct geographic areas - top geographies include California, Victoria, New South Wales.

Frequently Asked Questions

What is clinical trial NCT00244764 about?

NCT00244764 is a clinical study titled "GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma". Phase II, multi-center, two-stage study utilising a randomised discontinuation design to evaluate the safety and efficacy of GW786034 (pazopanib) in adult subjects with locally recurrent or metastatic clear-cell Renal Cell Carcinoma (RCC). After the interim analysis, the design was changed to an ope...

What is the current status of trial NCT00244764?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2005-10. Estimated completion is 2013-09.

What conditions does trial NCT00244764 study?

This clinical trial studies the following conditions: Carcinoma, Renal Cell.

What interventions are being tested in trial NCT00244764?

The interventions under investigation include: Placebo (DRUG), GW786034 (DRUG).

Who is sponsoring clinical trial NCT00244764?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00244764 being conducted?

This trial has 20 study locations across California, Colorado, Georgia, Indiana, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Carcinoma, Renal Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Carcinoma, Renal Cell

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.